UK pharmaceutical conglomerate AstraZeneca and India-based generics maker Ranbaxy Laboratories failed to have a landmark lawsuit ended early, say reports, and the companies will continue to face charges of an anticompetitive pay-for-delay agreement.
US District Judge William Young ruled Monday that the companies cannot end the jury trial early despite claims by the companies that the plaintiffs did not provide enough evidence of the alleged pay-for-delay scheme.
The charges surround the medication known as Nexium.
Reports say the case is the first of its kind since the US Supreme Court ruled against Actavis in deciding that pay-for-delay deals can be anticompetitive.
Meanwhile, reports say Teva Pharmaceuticals decided to settle the matter; details of the settlement, however, were not made public.
The trial began last October.
Full content: Bloomberg
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
ConocoPhillips Acquires Marathon Oil for $22.5 Billion in Major Energy Sector Consolidation
May 29, 2024 by
CPI
Judge Denies Amazon’s Bid to Dismiss FTC Lawsuit Over Prime Membership Practices
May 29, 2024 by
CPI
Germany and France Advocate for Major EU Competition Reform
May 29, 2024 by
CPI
Equifax Accused of Monopolizing Employment Verification Market in New Suit
May 29, 2024 by
CPI
Car Battery Makers to Challenge EU Cartel Charges in Brussels
May 29, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Merger Guidelines Retrospective
May 21, 2024 by
CPI
Mergers of Complements
May 21, 2024 by
CPI
Personality Traits, Private Equity, and Merger Analysis
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Lessons in the Importance of Incipiency, Modern Economics, and Monopsony
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Sharpening Merger Analysis
May 21, 2024 by
CPI